Biotech Values

[ciotera]

logic here is contradictory

The problem is they cannot afford to wait because someone else will beat them to the market. Once we have several DAA classes approved the IFN-free "party" may even start off-label (I personally don't think it will, but this just underscores the sense of urgency). And now with ABT results we know you don't really need a nuke, at least in naives, so GS-7977 is not going to become what Viread is in HIV. And without that type of monopoly power, GILD should be willing to split profits vs. risk missing them alltogether.